ASCLETIS-B (01672) rose more than 3% during the morning trading session. At the time of writing, the stock was up 2.06%, trading at HK$16.85 with a turnover of HK$7.3672 million. The company announced that it will present multiple projects via posters at the American Diabetes Association (ADA) 2026 Scientific Sessions, scheduled for June 5-8 in New Orleans, Louisiana. The presentations will include preclinical data for ASC39, an oral small-molecule amylin receptor agonist with selectivity and potency, similar to eloralintide, for the treatment of obesity. This presentation has been selected as a late-breaking poster. Notably, on April 27, ASCLETIS-B announced that the U.S. Phase II study for its core product, the oral small-molecule GLP-1R agonist ASC30 for type 2 diabetes, has successfully completed patient enrollment. This marks the product's second major indication following obesity, representing a key step in the company's commercialization strategy within the metabolic disease field.